[Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Yamane
T
T
Furukawa
Y
Y
Inoue
T
T
Sagawa
H
H
Yokomatsu
Y
Y
Kishida
T
T
Sasaki
A
A
Kojima
K
K
Sannomiya
Y
Y
Yoshikawa
T
T
D000284:Administration, Oral; D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D015122:Mercaptopurine / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D014801:Vitamin A / Q000008:administration & dosage*; D014807:Vitamin D / Q000008:administration & dosage*
D003561:Cytarabine; D014801:Vitamin A; D014807:Vitamin D; D011239:Prednisolone; D015122:Mercaptopurine; D003630:Daunorubicin